Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iTAG
- Development stage
- Preclinical
- Lead developer
- Vellum Biosciences
- Modality
- Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
iTAG is a reporter gene imaging platform developed by Vellum Biosciences for the non-invasive tracking of cell therapies, such as CAR T cells, in vivo. The system utilizes a modified version of the human dihydrofolate reductase (dHFR) enzyme as a reporter gene, which is expressed by the therapeutic cells. These cells can then be visualized using Positron Emission Tomography (PET) or Computed Tomography (CT) imaging following the administration of a matching radiolabeled trimethoprim (TMP)-derived imaging agent. This technology allows for the longitudinal monitoring of cell distribution, expansion, and persistence within the patient, providing critical data on the safety and efficacy of the cell therapy.
- Other names
- iTAG reporter gene systemdHFR reporter gene system
02
Targets
Nucleotide synth (Nucleotide synthesis enzymes)
Beyond the preview
Go deeper on iTAG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iTAG.